New study aims to catch rare cancers early in fanconi anemia patients
NCT ID NCT05687149
First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 3 times
Summary
This study follows people with Fanconi anemia, a rare inherited condition that raises the risk of certain cancers, especially squamous cell carcinoma. Researchers will screen 200 participants aged 12 and older every year for up to 10 years using exams, blood tests, and imaging to catch early signs of cancer. The goal is to understand how these cancers develop and improve early detection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2023
- Expected to finish
-
Dec 2035
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Persons \>=12 years with FA primarily from North America will be included in the study. Persons \< 12 years can also be included if they have a history of persistent oral potentially malignant lesions, dysphagia, or other concerning symptoms. Persons with FA from other countries are eligible provided they can travel to USA on their own.
- Ages
-
8 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: 1. On referral, persons \>= 12 years with FA primarily from North America will be included. An individual with FA who is 8 - 11 years can also be included if they have a history of persistent OPMLs, dysphagia, or other concerning symptoms. 2. Individuals with prior cancer diagnosis are eligible. 3. Individuals from other countries are eligible provided they can travel to the USA on their own. 4. Ability to understand and/or the willingness of the individual, parent, LAR, or minor s legal guardian to provide informed consent. EXCLUSION CRITERIA: 1. Referred individuals for whom reported diagnosis of FA cannot be verified. 2. Inability of the individual, parent, LAR, or legal guardian to understand and be willing to sign a written informed consent document.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fanconi anemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily pill boost blood counts in fanconi anemia?
- Can a single drink reveal how alcohol triggers oral cancer?
- Gene therapy aims to fix bone marrow failure in fanconi anemia
- New transplant method aims to reduce complications in bone marrow failure patients
- New MRI method could spot oral cancer early in rare disease patients
- New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients